Skip to main content
. 2024 Jul 12;22:79. doi: 10.1186/s12958-024-01255-1

Table 6.

Subgroup analyses (categorized by types of adenomyosis) of patients with atosiban or without

Focal adenomyosis (n = 216) Diffuse adenomyosis (n = 100)
Parameters

Atosiban

(n = 102)

Control

(n = 114)

p value

Atosiban

(n = 55)

Control

(n = 45)

p value
Age (years) 37.3 ± 4.5 38.0 ± 3.7 0.213 39.0 ± 3.8 38.7 ± 3.9 0.685
Body mass index (kg/m2) 24.0 ± 4.0 23.5 ± 4.3 0.398 23.2 ± 3.4 23.8 ± 4.3 0.382
Infertility duration (years) 4.4 ± 3.1 5.3 ± 3.3 0.040 5.0 ± 3.5 5.4 ± 4.4 0.596
Previous IVF attempts (n) 2.7 ± 2.4 3.1 ± 2.4 0.200 3.2 ± 2.7 3.3 ± 2.2 0.952
Primary infertility (%) 49.0%(50/102) 50.9%(58/114) 0.785 45.5%(25/55) 37.8%(17/45) 0.439
FSH (IU/L) 5.7 ± 3.0 5.1 ± 3.2 0.150 4.7 ± 2.0 5.3 ± 2.1 0.181
Anti-Müllerian hormone (ng/ml) 4.03 ± 4.02 3.43 ± 2.93 0.217 2.18 ± 1.88 2.83 ± 2.08 0.104
Endometrial thickness (mm) 11.8 ± 2.2 11.8 ± 2.2 0.948 11.3 ± 2.4 11.1 ± 2.2 0.674
ET day (%) 0.162 0.562
Day 3 ET 52.0%(53/102) 61.4%(70/114) 72.7%(40/55) 77.8%(35/45)
Day 5 ET 48.0%(49/102) 38.6%(44/114) 27.3%(15/55) 22.2%(10/45)
At least one top-quality embryos transferred (%) 80.4%(82/102) 77.2%(88/114) 0.566 76.4%(42/55) 82.2%(37/45) 0.474
Biochemical pregnancy rate (%) 66.7%(68/102) 60.5%(69/114) 0.350 43.6%(24/55) 15.6%(7/45) 0.003
Clinical pregnancy rate (%) 57.8%(59/102) 59.6%(68/114) 0.788 38.2%(21/55) 13.3%(6/45) 0.005
Ongoing pregnancy rate (%) 52.0%(53/102) 46.5%(53/114) 0.422 36.4%(20/55) 11.1%(5/45) 0.004
Live birth rate (%) 50.0%(51/102) 43.9%(50/114) 0.367 32.7%(18/55) 11.1%(5/45) 0.011
Miscarriage rate (%) 13.6%(8/59) 26.5%(18/68) 0.072 14.3%(3/21) 16.7%(1/6) 0.885
Early miscarriage rate (%) 10.2%(6/59) 22.1%(15/68) 0.072 4.8%(1/21) 16.7%(1/6) 0.326
Late miscarriage rate (%) 3.4%(2/59) 4.4%(3/68) 0.768 9.5%(2/21) 0.0%(0/6) 0.432

Data are presented as the mean ± standard deviation and % (n)

IVF, in vitro fertilization; FSH, follicular stimulating hormone; ET, embryo transfer